Genzyme hopes for higher bid from Sanofi-Aventis
Wednesday 04 August 2010
Genzyme, the pioneering US biotechnology company whose drugs are among the most expensive in the world, is plotting tactics to extract as much money as possible for its shareholders in a takeover by the French pharmaceutical giant Sanofi-Aventis.
The two sides began formal talks after Sanofi detailed a preliminary $18.4bn (£11.5bn) offer in a letter sent to Genzyme late on Monday, but the US company's shares dipped yesterday as hopes of a bidding war ebbed. At lunchtime, they remained modestly above the value of Sanofi's $69 a share all-cash offer at $70 apiece.
GlaxoSmithKline, the UK's largest drug maker, is believed to have ruled itself out as a potential white knight, citing price and the fact that it has already expanded its portfolio of medicines for rare diseases through the licensing deal last December with JCR of Japan. Pfizer, another potential suitor, also appeared cool about joining the fray yesterday. The company's finance director, Frank D'Amelio, speaking at its quarterly results, said he was looking only at "bolt-on" acquisitions up to "several billion" dollars.
Johnson & Johnson, the maker of Tylenol cough medicine and Band-Aid bandages, also has a large war chest for acquisitions and has been named as a potential bidder.
The acquisition of Genzyme would propel Sanofi to a leading position in so-called "orphan" drugs, medicines for rare and difficult-to-treat diseases, which are given special privileges by regulators and insurers that make them more profitable. Genzyme generated sales of $4.5bn last year from treatments for rare hereditary disorders such as Gaucher and Fabry disease. Its Gaucher disease treatment Cerezyme alone generated $1.2bn of sales in 2009. Costing more than $200,000 a year, it is one of the most expensive drugs in the world.
"The blockbuster era seems to be on the wane," said Kevin Gorman at the pharmaceuticals consultancy Putnam Associates. "The dramatically unmet needs are in rare diseases."
Sanofi has set off on the acquisition trail to replace revenues lost as its medicines face competition from copycats. It issued a profit warning last month after US regulators approved a generic version of its Lovenox blood thinner. Yesterday, two major investors warned it should not dramatically raise its bid, and certainly not to the $80 per share that Genzyme's board has indicated it wants.
- 1 Rape threats, death threats and a police investigation after video poking fun at an Islamic Party in Malaysia goes viral
- 2 Katie Hopkins attacked me on Twitter — so I reported her to the police for inciting racial hatred
- 3 Gamers confess the worst things they've done in The Sims
- 4 6-year-old writes ice cold Valentine's card to his stepmother
- 5 Syrian child photographed 'surrendering to camera because she thought it was a gun'
Rape threats, death threats and a police investigation after video poking fun at an Islamic Party in Malaysia goes viral
Why Robin Williams safeguarded himself against a morbid trend in advertising
Jeremy Clarkson 'could be given minder' ahead of a potential Top Gear return
6-year-old writes ice cold Valentine's card to his stepmother
Jeremy Clarkson to become 'special adviser on transport' to David Cameron
Katie Hopkins attacked me on Twitter — so I reported her to the police for inciting racial hatred
Street preacher quoting from the Bible fined for calling homosexuality an 'abomination'
Woman filmed launching racist tirade against men on the Tube for speaking in 'own lingo'
David Cameron calls Labour 'hopeless, sneering socialists' while announcing 7-day NHS plans
Revealed: Putin's army of pro-Kremlin bloggers
Katie Hopkins reported to the police for race hatred by Labour MP Simon Danczuk after tweet about Pakistani men
iJobs Money & Business
£20000 per annum + commission: SThree: Sthree have an exciting opportunity for...
£18000 - £32000 per annum: Recruitment Genius: A Telesales Executive is requir...
£45000 - £50000 per annum + benefits : Ashdown Group: A highly successful, glo...
£50,000 - £55,000: Neil Pavier: Are you a professionally qualified commercial ...